Viridian Therapeutics(DE:1S1)
€27.60+1.00 (+3.76%)
DE:1S1
Viridian Therapeutics stock drug pipeline
€27.60
At close:+1.00 (+3.76%)
Viridian Therapeutics (1S1) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vrdn-003, Autoinjector | Thyroid Eye Disease | Phase III | Recruiting | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Aug 07, 2025 | ― |
| Vrdn-003 | Thyroid Eye Disease (Ted) | Phase III | Recruiting | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Jan 27, 2025 | ― |
| Vrdn-003 | Thyroid Eye Disease | Phase III | Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Oct 01, 2024 | ― |
| Vrdn-003 | Thyroid Eye Disease | Phase III | Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Oct 01, 2024 | ― |
| Vrdn-001 10 Mg/Kg, Vrdn-001 3 Mg/Kg | Thyroid Eye Disease | Phase III | Active Not Recruiting | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | Apr 22, 2024 | ― |
| Intervention/Treatment | Thyroid Eye Disease | Phase III | Completed | An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 | Dec 12, 2023 | ― |
| Veligrotug (Vrdn-001) | Thyroid Eye Disease | Phase III | Completed | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | Aug 25, 2023 | ― |
| Vrdn-001 Phase 3 Cohort (Thrive) | Thyroid Eye Disease | Phase III | Completed | A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | Dec 15, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vrdn-003, Autoinjector | Phase III | Thyroid Eye Disease | Recruiting | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Aug 07, 2025 | ― |
| Vrdn-003 | Phase III | Thyroid Eye Disease (Ted) | Recruiting | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Jan 27, 2025 | ― |
| Vrdn-003 | Phase III | Thyroid Eye Disease | Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Oct 01, 2024 | ― |
| Vrdn-003 | Phase III | Thyroid Eye Disease | Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Oct 01, 2024 | ― |
| Vrdn-001 10 Mg/Kg, Vrdn-001 3 Mg/Kg | Phase III | Thyroid Eye Disease | Active Not Recruiting | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | Apr 22, 2024 | ― |
| Intervention/Treatment | Phase III | Thyroid Eye Disease | Completed | An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 | Dec 12, 2023 | ― |
| Veligrotug (Vrdn-001) | Phase III | Thyroid Eye Disease | Completed | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | Aug 25, 2023 | ― |
| Vrdn-001 Phase 3 Cohort (Thrive) | Phase III | Thyroid Eye Disease | Completed | A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | Dec 15, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Viridian Therapeutics, Inc. (DE:1S1) have in its pipeline
Viridian Therapeutics DE:1S1 is currently developing the following drugs: Vrdn-003, Autoinjector, Vrdn-003, Vrdn-001 10 Mg/Kg, Vrdn-001 3 Mg/Kg, Intervention/Treatment, Veligrotug (Vrdn-001), Vrdn-001 Phase 3 Cohort (Thrive). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
